While there already was an increasing trend ( β = 0.6044, s.e. = 0.0864) in milligrams per dosage pre-introduction, the dosage increased with 10 mg (s.e. = 4.1277) post-introduction.
← all excerpts
The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.
1
—
—